GeoVax's Multi-Antigen COVID-19 Vaccine Shows Promise for Immunocompromised Patients
GeoVax Labs will present clinical data demonstrating that its GEO-CM04S1 vaccine generates cross-variant antibody and robust cellular immune responses in immunocompromised patients with hematologic malignancies, potentially addressing a critical gap in COVID-19 protection for vulnerable populations.
GeoVax Labs, Inc. announced that clinical data for its next-generation COVID-19 vaccine, GEO-CM04S1, will be presented at two international scientific conferences in September 2025. The data highlights the vaccine's performance in immunocompromised patients with hematologic malignancies, showing cross-variant antibody and robust cellular immune responses.
At the 6th ESCMID Conference on Vaccines in Lisbon, Portugal, Chief Medical Officer Kelly T. McKee, Jr. will present a poster titled "GEO-CM04S1, a multi-antigen COVID-19 vaccine for immunocompromised individuals: clinical evaluation to date" on September 12. For more information on this conference, visit the ESCMID conference website.
At the International Workshop on Chronic Lymphocytic Leukemia in Krakow, Poland, Professor Alexey V. Danilov from City of Hope National Medical Center will present Phase II randomized study results on September 15. The poster, titled "MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia (CLL) compared with mRNA-based vaccine: initial results from a Phase II randomized study," suggests superior immune responses compared to existing mRNA vaccines. Conference details are available at the iwCLL event page.
The significance of these findings lies in addressing a critical healthcare gap. Immunocompromised patients, particularly those with hematologic cancers, often respond poorly to current COVID-19 vaccines, leaving them vulnerable to severe outcomes. GEO-CM04S1's multi-antigen approach appears to overcome this limitation, potentially offering better protection for this high-risk population. This development could lead to more effective vaccination strategies for immunocompromised individuals worldwide.
GeoVax's vaccine is currently in three Phase 2 clinical trials, evaluating it as a primary vaccine for immunocompromised patients, a booster for CLL patients, and a more durable booster for healthy individuals previously vaccinated with mRNA vaccines. The company's progress with GEO-CM04S1 represents an important advancement in COVID-19 vaccine technology, particularly for vulnerable patient populations who have remained at elevated risk throughout the pandemic.